In patients with RA, a rapid decrease in levels of acute phase reactants of inflammation, C-reactive protein, and fibrinogen, as well as the serum cytokines, IL-1ß and IL-6, and IL-1 receptor antagonist is observed following treatment with adalimumab (Abbott Laboratories; Barrera et al. 2001). Serum levels of matrix metal-loproteinases-1 and -3 and other markers of synovial cell activation and cartilage erosion are also decreased following adalimumab administration (Abbott Laboratories 2006; Weinblatt et al. 2003). An immunology study assessing the efficacy of adalimumab plus MTX in patients with RA demonstrated that normal immune function is preserved during adalimumab therapy (Kavanaugh et al. 2002). Adalimumab treatment did not significantly alter the numbers of peripheral blood natural killer cells, monocytes/macrophages, B cells, or major T-cell subsets; moreover, in vitro lymphocyte proliferation, delayed-type hypersensitivity reactivity, and antibody responses to pneumococcal antigen vaccination were maintained during therapy (Kavanaugh et al. 2002).
Was this article helpful?
Do You Suffer From the Itching and Scaling of Psoriasis? Or the Chronic Agony of Psoriatic Arthritis? If so you are not ALONE! A whopping three percent of the world’s populations suffer from either condition! An incredible 56 million working hours are lost every year by psoriasis sufferers according to the National Psoriasis Foundation.